TD Private Client Wealth’s Pacira BioSciences PCRX Stock Holding History

TD Private Client Wealth’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-477	Closed	-$13.6K	–	1293
2024 Q2	$13.6K	Buy	477 +427	+854%	+$12.2K	﹤0.01%	995
2024 Q1	$1.46K	Sell	50 -93	-65%	-$2.86K	﹤0.01%	1152
2023 Q4	$4.83K	Hold	143	–	–	﹤0.01%	1119
2023 Q3	$4.39K	Sell	143 -8	-5%	-$288	﹤0.01%	1129
2023 Q2	$6.05K	Hold	151	–	–	﹤0.01%	1109
2023 Q1	$6.16K	Buy	+151	New	+$6.01K	﹤0.01%	1089

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

TD Private Client Wealth's PCRX Position: Q3 2024 in Review

TD Private Client Wealth sold out of Pacira BioSciences (PCRX) in Q3 2024, closing a stake of 477 shares — an estimated $13.6K sold.

TD Private Client Wealth first reported a position in PCRX in Q1 2023 and held it in 6 quarters. The position peaked at $13.6K in Q2 2024. 239 funds tracked by Wall St. Rank hold PCRX as of Q3 2024.

TD Private Client Wealth reported no remaining Pacira BioSciences position as of Q3 2024 after selling out during the quarter.
TD Private Client Wealth sold 477 Pacira BioSciences shares in Q3 2024, an estimated $13.6K.
TD Private Client Wealth first reported a position in Pacira BioSciences in Q1 2023 and held it in 6 quarters.
TD Private Client Wealth's Pacira BioSciences position peaked at $13.6K in Q2 2024.
239 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2024.

Based on TD Private Client Wealth's 13F filing for Q3 2024, filed 18 Nov 2024.